362 results match your criteria Urticaria Solar


[Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].

Ned Tijdschr Tandheelkd 2020 Apr;127(4):237-243

The medicament afamelanotide is an analogue of endogenous ?-melanocyte-stimulating hormone. It promotes cutaneous pigmentation, providing protection from sunlight. In dermatology, afamelanotide seems to establish therapeutic results for polymorphic light eruption, solar urticaria, erythropoietic protoporphyria, Hailey-Hailey disease, vitiligo and acne vulgaris. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5177/ntvt.2020.04.19115DOI Listing

Good things come to those who wait: Successful response of solar urticaria to omalizumab after 1 year of treatment.

Photodermatol Photoimmunol Photomed 2020 May 19. Epub 2020 May 19.

Dermatology Unit, University of Rome Tor Vergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12577DOI Listing

Establishment of the basophil activation test to detect photoallergens in solar urticaria.

J Allergy Clin Immunol Pract 2020 Apr 26. Epub 2020 Apr 26.

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2020.04.042DOI Listing

Transient Pruritic Erythema as a Forme Fruste of Solar Urticaria.

Isr Med Assoc J 2020 Apr;22(4):227-231

Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Background: Solar urticaria (SU) is a rare and disabling photodermatosis. SU typically manifests as urticarial wheals and erythema appearing shortly after sun exposure. SU is often initially diagnosed clinically with subsequent confirmation through photoprovocation tests. Read More

View Article

Download full-text PDF

Source

A qualitative study of knowledge, behaviour and attitudes regarding vitamin D acquisition among patients with photosensitivity disorders.

Photodermatol Photoimmunol Photomed 2020 Apr 10. Epub 2020 Apr 10.

Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology Medicine and Health, Centre for Dermatology Research, School of Biological Sciences, University of Manchester, Manchester Academic Health Science Centre and Salford Royal NHS Foundation Trust, Manchester, UK.

Background: Cutaneous exposure to sunlight is a major source of vitamin D. Individuals with photosensitivity disorders have symptoms provoked by sunlight and may not achieve the brief sunlight exposures that convey vitamin D acquisition.

Objective: To explore knowledge, behaviour and attitudes towards vitamin D and its acquisition in patients with photosensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12561DOI Listing

Solar urticaria caused by visible light in a 33-year-old male refractory to treatment with omalizumab.

Photodermatol Photoimmunol Photomed 2020 Mar 5. Epub 2020 Mar 5.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12545DOI Listing

Comparison of racial distribution of photodermatoses in USA academic dermatology clinics: A multicenter retrospective analysis of 1080 patients over a 10-year period.

Photodermatol Photoimmunol Photomed 2020 May 12;36(3):233-240. Epub 2020 Mar 12.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Background: Previous studies at single academic institutions have identified variations in the prevalence of photodermatoses among racial groups. The purpose of the study was to compare the distribution of photodermatoses between Whites and Blacks at four academic medical centers in the USA.

Methods: A retrospective chart review was performed at four institutions' general dermatology clinics using diagnoses consistent with the International Classification of Disease (ICD), Ninth and Tenth Revisions, codes related to photodermatoses between August 2006 and August 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12543DOI Listing

Characteristics and clinical significance of augmentation spectra in solar urticaria.

J Dermatol 2020 Apr 21;47(4):369-377. Epub 2020 Jan 21.

Department of Dermatology, Kansai Medical University, Osaka, Japan.

Solar urticaria has unique spectra, such as inhibition and augmentation. The clinical significance of these spectra, especially augmentation, is not well understood. Reported cases of solar urticaria with augmentation spectra are extremely rare in the published English-language work. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15234DOI Listing

Phototherapy in the Evaluation and Management of Photodermatoses.

Dermatol Clin 2020 Jan 18;38(1):71-77. Epub 2019 Oct 18.

Department of Dermatology, Henry Ford Health System, 3031 West Grand Boulevard, Suite 800, Detroit, MI 48202, USA. Electronic address:

Ultraviolet light (UV) and visible light are important components in the diagnosis of photodermatoses, and UV has the unique ability to also be used to manage photodermatoses. Phototesting, provocative light testing, and photopatch testing can provide important information in diagnosing patients with photodermatoses; phototesting can be used to determine the starting dose for phototherapy in these patients. Once photosensitivity is established, narrowband UVB and UVA1 therapy have helped to improve the quality of life of photosensitive patients, such as those with polymorphous light eruption, chronic actinic dermatitis, and solar urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2019.08.007DOI Listing
January 2020

Solar urticaria treated with omalizumab.

Cutis 2019 Jul;104(1):E4-E5

Allergy and Immunology Service, Tripler Army Medical Center, Honolulu, Hawaii, USA.

View Article

Download full-text PDF

Source
July 2019
2 Reads

Incapacitating solar urticaria: successful treatment with omalizumab.

An Bras Dermatol 2019 Jul 29;94(3):331-333. Epub 2019 Jul 29.

Dermatology Department, Centro Hospitalar de Leiria, Leiria, Portugal.

Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20198109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668931PMC
July 2019
2 Reads

Solar Urticaria, a Disease with Many Dark Sides: Is Omalizumab the Right Therapeutic Response? Reflections from a Clinical Case Report.

Open Med (Wars) 2019 7;14:403-406. Epub 2019 Jun 7.

Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy Allergy an Clinical Immunology Unit, AUSL 04 Teramo, Italy.

Solar urticaria is a rare type of photodermatosis that significantly reduces the quality of life of the subjects affected, with a risk of anaphylaxis should the entire body be exposed to the sun. Patients are forced to modify and limit their normal activities, and since the symptoms are triggered by exposure to sun, which is difficult if not impossible to avoid in everyday life, a safe and effective therapy appears to be essential. Unfortunately, traditional therapies in a discrete number of patients are unable to provide adequate and safe answers. Read More

View Article

Download full-text PDF

Source
http://www.degruyter.com/view/j/med.2019.14.issue-1/med-2019
Publisher Site
http://dx.doi.org/10.1515/med-2019-0042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572395PMC
June 2019
19 Reads

Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab.

J Am Acad Dermatol 2019 May 28. Epub 2019 May 28.

Dermatology Department, Photobiology Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.05.070DOI Listing
May 2019
7 Reads

Evaluation of nine patients with solar urticaria during summer.

G Ital Dermatol Venereol 2019 Mar 29. Epub 2019 Mar 29.

Allergological and Occupational Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06176-5DOI Listing
March 2019
7 Reads

Real-life experience in the treatment of solar urticaria: retrospective cohort study.

Clin Exp Dermatol 2019 Jul 13;44(5):e164-e170. Epub 2019 Apr 13.

Photodermatosis Service, Department of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

Background: Solar urticaria (SU) is a rare photodermatosis causing a significant impact on patients' quality of life (QoL), and treatment is often challenging.

Aim: To analyse clinical experience with a tailored stepwise therapeutic approach.

Methods: A retrospective cohort design was used. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ced.13960
Publisher Site
http://dx.doi.org/10.1111/ced.13960DOI Listing
July 2019
42 Reads

Solar urticaria - An Australian case series of 83 patients.

Australas J Dermatol 2019 May 25;60(2):110-117. Epub 2018 Dec 25.

St Vincent's Hospital, Melbourne, Victoria, Australia.

Solar urticaria (SU) is a rare form of urticaria with a pathogenesis that is poorly understood. It affects all skin types, can be difficult to diagnose, and is challenging to manage effectively. We conducted a retrospective review of patients with SU in our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12975DOI Listing
May 2019
11 Reads

Successful treatment of solar urticaria with UVA1 hardening in three patients.

Photodermatol Photoimmunol Photomed 2019 May 8;35(3):193-195. Epub 2019 Jan 8.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Solar urticaria (SU) is an uncommon photodermatosis that presents with sensitivity to ultraviolet (UV) or visible light which triggers urticarial lesions. Treatment of SU is a challenge and usually involves antihistamines and photoprotection as a first-line treatment. Phototherapy regimens are recommended if these first-line treatments fail to control the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12447DOI Listing
May 2019
12 Reads

Unexpected photosensitivity - a patient with dermatomyositis and concomitant solar urticaria.

J Eur Acad Dermatol Venereol 2019 Apr 9;33(4):e149-e150. Epub 2019 Jan 9.

Department of Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15379DOI Listing
April 2019
9 Reads

Solar Angioedema: A report of a patient and a review of literature.

Photodermatol Photoimmunol Photomed 2019 05 6;35(3):187-189. Epub 2019 Jan 6.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12445DOI Listing
May 2019
5 Reads

Afamelanotide in the Treatment of Dermatologic Disease

Skin Therapy Lett 2018 11;23(6):6-10

Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE), vitiligo, acne, and Hailey-Hailey disease. Its relatively low risk side effect profile makes it an attractive treatment option and also paves the way for innovative use in other disorders. Read More

View Article

Download full-text PDF

Source
November 2018
16 Reads

Evaluating patient responses to omalizumab in solar urticaria.

Photodermatol Photoimmunol Photomed 2019 Jan 25;35(1):57-65. Epub 2018 Nov 25.

Centre for Dermatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12434DOI Listing
January 2019
9 Reads

Inducing Light Tolerance With Narrowband UV-B Therapy in Solar Urticaria.

Authors:
P Aguilera

Actas Dermosifiliogr 2018 Dec 9;109(10):853. Epub 2018 Oct 9.

Servicio de Dermatología, Hospital Clínic, Barcelona, España. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00017310183033
Publisher Site
http://dx.doi.org/10.1016/j.ad.2018.06.009DOI Listing
December 2018
11 Reads

Polymorphous light eruption with complication of solar urticaria revealed by phototesting.

J Dermatol 2019 05 10;46(5):e148-e149. Epub 2018 Oct 10.

Department of Dermatology, Kansai Medical University, Osaka, Japan.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1346-8138.14670
Publisher Site
http://dx.doi.org/10.1111/1346-8138.14670DOI Listing
May 2019
14 Reads

Induction of Light Tolerance Using Narrowband UV-B in Solar Urticaria.

Actas Dermosifiliogr 2018 Dec 8;109(10):888-892. Epub 2018 Sep 8.

Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.

Introduction: Solar urticaria is an uncommon photodermatosis. First-line treatment is with antihistamines; second-line treatment includes induction of light tolerance using UV phototherapy.

Objectives: We aimed to describe and evaluate the effectiveness of a desensitization protocol with narrowband UV-B in patients with solar urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.06.005DOI Listing
December 2018
25 Reads

How to Approach Chronic Inducible Urticaria.

J Allergy Clin Immunol Pract 2018 Jul - Aug;6(4):1119-1130

Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Tex.

Chronic inducible urticaria (CIndU) is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema or both, as a response to specific triggers. CIndU includes both physical (symptomatic dermographism, cold and heat urticaria, delayed pressure urticaria, solar urticaria, and vibratory urticaria) and nonphysical urticarias (cholinergic urticaria, contact and aquagenic urticaria). Here, we review the different forms of CIndU with an emphasis on symptomatic dermographism, cold urticaria, cholinergic urticaria, and delayed pressure urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.03.007DOI Listing
October 2019
91 Reads

Photocontact Dermatitis and Its Clinical Mimics: an Overview for the Allergist.

Clin Rev Allergy Immunol 2019 Feb;56(1):32-40

Department of Dermatology, The University of Texas Southwestern, 5323 Harry Hines Blvd, Dallas, TX, 75390-9069, USA.

Photo-contact dermatitis (PCD) describes the adverse cutaneous reaction that occurs in some patients as a result of simultaneous exposure to a contactant and to light. PCD can be subdivided into photo-allergic and photo-irritant dermatitis depending on whether the contactant respectively invokes an allergic or irritant reaction. Photo-irritant reactions are commonly caused by plants, psoralens, and medications taken internally, whereas photo-allergic reactions are commonly caused by sunscreens and topical nonsteroidal anti-inflammatory medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12016-018-8696-xDOI Listing
February 2019
39 Reads

Herbal sun protection agents: Human studies.

Clin Dermatol 2018 May - Jun;36(3):369-375. Epub 2018 Mar 21.

Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY.

Topical sunscreens are the mainstay for protection from ultraviolet (UV) radiation. With skin cancer rates on the rise and great interest in reversing or preventing the effects of photoaging, new molecules with potential to defend against UV damage have received a great deal of attention. Specifically, there is a growing interest in herbal substances that offer protection against the damaging effects of UV rays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2018.03.014DOI Listing
November 2018
45 Reads

Erythropoietic protoporphyria and solar urticaria.

Authors:
P M Farr

Br J Dermatol 2018 08 10;179(2):542. Epub 2018 Jun 10.

Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, U.K.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjd.16684
Publisher Site
http://dx.doi.org/10.1111/bjd.16684DOI Listing
August 2018
18 Reads

Omalizumab for the Treatment of Solar Urticaria: Case Series and Systematic Review of the Literature.

J Allergy Clin Immunol Pract 2018 Jul - Aug;6(4):1198-1204.e3. Epub 2018 Mar 20.

Photodermatosis Clinic, Department of Dermatology, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

Background: Solar urticaria (SU) is a rare photodermatosis causing a significant impact on patients' quality of life. Although the condition can be controlled with phototherapy and/or a combination therapy of antihistamines and leukotriene antagonist in most patients, a subset of patients require additional therapy with omalizumab; however, efficacy data are sparse.

Objective: The objective of this study was to determine the efficacy and safety of omalizumab for treating SU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.02.032DOI Listing
October 2019
13 Reads

Solar urticaria in 145 patients: Assessment of action spectra and impact on quality of life in adults and children.

Photodermatol Photoimmunol Photomed 2018 Jul 14;34(4):262-268. Epub 2018 Apr 14.

Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Background: Solar urticaria (SU) is a rare chronic inducible urticaria triggered via uncharacterized chromophores. We detail responses of a large patient series to monochromator phototesting and broadband ultraviolet radiation (UVR); relationship to life quality is explored.

Methods: Retrospective review of all SU patients undergoing standardized diagnostic photoinvestigation at a specialist centre during 2000-2016. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/phpp.12385
Publisher Site
http://dx.doi.org/10.1111/phpp.12385DOI Listing
July 2018
12 Reads

Effectiveness in the treatment of solar urticaria with omalizumab: Report of 7 cases.

Med Clin (Barc) 2018 12 8;151(11):460-461. Epub 2018 Mar 8.

Servicio de Dermatología, Hospital Universitari i Politécnic La Fe, Valencia, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2018.01.003DOI Listing
December 2018
12 Reads

Paediatric solar urticaria: a case series.

Br J Dermatol 2018 06 22;178(6):1453-1454. Epub 2018 Apr 22.

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.16325DOI Listing
June 2018
13 Reads

Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature.

Photodermatol Photoimmunol Photomed 2018 May 4;34(3):194-199. Epub 2018 Jan 4.

Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Background: Solar urticaria (SU) is a rare photodermatosis. Treatment is challenging, and outcomes are often disappointing. Omalizumab is an anti-IgE, currently approved for treatment of chronic spontaneous urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12370DOI Listing
May 2018
21 Reads

[Solar urticaria. Case report and literature review].

Rev Alerg Mex 2017 Jul-Sep;64(3):371-375

Universidad de Antioquia, IPS Universitaria, Grupo de Alergología Clínica y Experimental, Medellín, Colombia.

Background: Solar urticaria is a rare type of inducible urticaria characterized by wheal and erythema formation shortly after exposure to sunlight or to an artificial light source; its pathophysiology is not yet entirely understood. The treatment of choice, in addition to exposure avoidance, consists in antihistamine administration.

Clinical Case: This is the case of a 27-year-old woman with no personal history of allergic diseases and with a 2-year history of erythema and wheals in photo-exposed areas associated with sunlight exposure for periods longer than 10 minutes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29262/ram.v64i3.202DOI Listing
July 2019
10 Reads

Solar urticaria developing in patients with erythropoietic protoporphyria: a clue to the pathogenesis of solar urticaria?

Br J Dermatol 2018 02 20;178(2):567-568. Epub 2018 Jan 20.

Photodermatology Department, St John's Institute of Dermatology, Guy's Hospital, London, SE1 9RH, U.K.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.15882DOI Listing
February 2018
11 Reads

Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence.

J Allergy Clin Immunol 2018 02 24;141(2):638-649. Epub 2017 Jul 24.

Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Background: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H-antihistamine resistant.

Objective: From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2017.06.032DOI Listing
February 2018
53 Reads

Long-term management of chronic spontaneous urticaria with omalizumab.

Clin Exp Dermatol 2017 Oct 25;42(7):735-742. Epub 2017 Jun 25.

Dermatology Department, Coimbra University Hospital Centre, Coimbra, Portugal.

Background: Clinical trials have shown the efficacy of omalizumabs efficacy in refractory chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), but real-life management strategies are lacking.

Aim: To assess the long-term efficacy and safety of omalizumab, and to identify predictive factors and optimum dosage regimens.

Methods: This was a prospective study of 13 patients (11 women, 2 men) with severe CSU [weekly urticaria activity score (UAS7) > 28] resistant to anti-H1 antihistamines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.13173DOI Listing
October 2017
47 Reads

Solar urticaria with an augmentation spectrum in a child.

J Dermatol 2017 Sep 23;44(9):e214-e215. Epub 2017 May 23.

Department of Dermatology, Kansai Medical University, Hirakata, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.13914DOI Listing
September 2017
57 Reads

[SOLAR URTICARIA].

Harefuah 2016 Oct;155(10):604-607

Photodermatoses Clinic, Department of Dermatology, Rabin Medical Center, Petah Tikva, Israel.

Introduction: Solar urticaria is a rare photodermatosis. It belongs to the group of physical urticarias. In this particular urticarial, erythema and whealing accompanied by pruritus occur seconds to minutes after exposure to light. Read More

View Article

Download full-text PDF

Source
October 2016
21 Reads

Response to Omalizumab in Solar Urticaria: Report of 3 Cases.

Actas Dermosifiliogr 2017 Oct 27;108(8):e53-e55. Epub 2017 Apr 27.

Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.

We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2016.08.011DOI Listing
October 2017
15 Reads

Refractory solar urticaria successfully treated with omalizumab with normalization of phototest.

Actas Dermosifiliogr 2017 Jul - Aug;108(6):593-594. Epub 2017 Feb 4.

Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2016.11.015DOI Listing
October 2018
16 Reads

Solar urticaria with a wide action spectrum from UVB to visible light complicated with UVA-induced polymorphous light eruption.

Photodermatol Photoimmunol Photomed 2017 05 13;33(3):172-175. Epub 2017 Mar 13.

Department of Dermatology, Kansai Medical University, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12300DOI Listing
May 2017
48 Reads

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Clin Pharmacokinet 2017 08;56(8):815-823

Stadtspital Triemli, Institute of Laboratory Medicine, Zurich, Switzerland.

Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation. The loss-of-function variants of the MC1R present in fair-skinned Caucasians are less effectively activated by the natural hormone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0501-5DOI Listing
August 2017
63 Reads

[Partial response of solar urticaria to omalizumab therapy].

Hautarzt 2017 Jun;68(6):492-496

Klinik für Hautkrankheiten und Allergologie, HELIOS Vogtland-Klinikum Plauen GmbH, 100153, 08505, Plauen, Deutschland.

The treatment of solar urticaria is regarded as difficult. In some cases good responses to the anti-IgE antibody omalizumab (Xolair®), approved for treatment of chronic spontaneous urticaria, have been reported. We report on a 50-year-old Caucasian woman who for the last 5 years has developed localized itching and stinging erythemas following exposure to sunlight accompanied sometimes by anaphylactic reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-016-3913-0DOI Listing
June 2017
45 Reads

Clinical and etiologic evaluation of the children with chronic urticaria.

Allergy Asthma Proc 2016 11;37(6):450-457

Pediatric Allergy and Immunology, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey.

Background: Chronic urticaria (CU) is a skin disorder defined as daily or almost daily exhibition of pruritic and transient wheals that last for 6 weeks. CU is divided into two subtypes: chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).

Objectives: To evaluate the clinical features, possible causes, associated findings, and laboratory results of different subtypes of CU in children according to a new classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2500/aap.2016.37.4010DOI Listing
November 2016
46 Reads

Solar urticaria: Epidemiology and clinical phenotypes in a Spanish series of 224 patients.

Actas Dermosifiliogr 2017 Mar 25;108(2):132-139. Epub 2016 Oct 25.

Unidad de Fotobiología Dermatológica y Oncología Cutánea, Departamento de Dermatología y Medicina, Universidad de Málaga, Málaga, España.

Background: Solar urticaria is a chronic inducible urticaria also classified as an idiopathic dermatosis. The objective of this paper is to define the phenotypic characteristics of solar urticaria and to evaluate its incidence.

Material And Method: This was a retrospective multicenter study in which data were gathered on the epidemiology and clinical, photobiologic, laboratory, and therapeutic characteristics of solar urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2016.09.003DOI Listing
March 2017
20 Reads

Solar urticaria induced by visible light: successful treatment with omalizumab.

Clin Exp Dermatol 2016 Dec 20;41(8):890-892. Epub 2016 Oct 20.

Department of Dermatology and Allergy Unit, University Hospital, Basel, Switzerland.

We report the case of a 53-year-old man with solar urticaria (SU) not responding to histamine antagonist therapy. Using intradermal testing with the patient's irradiated serum, we demonstrated that his SU was elicited by visible light only. This type of SU is uncommon, and makes preventive measures such as sun block largely ineffective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.12951DOI Listing
December 2016
20 Reads

Omalizumab in the Treatment of Chronic Inducible Urticaria.

Actas Dermosifiliogr 2017 Jun 5;108(5):423-431. Epub 2016 Oct 5.

Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.

Omalizumab is a recombinant humanized monoclonal antibody that inhibits immunoglobulin E. It has been approved for the treatment of severe asthma and chronic spontaneous urticaria refractory to other treatments. Its use in the management of chronic inducible urticaria (a type triggered by certain stimuli) is still considered off-label, although this use has been discussed in some consensus papers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2016.07.018DOI Listing
June 2017
42 Reads